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Background: Ectopic TSH-secreting pituitary adenoma (TSH-oma) is a very unusual disorder. To date, there are only
four cases reported. It is difficult to distinguish ectopic cases from both regular TSH-omas and resistance to thyroid
hormone (RTH).
Case presentation: A newly identified case of ectopic TSH-oma arising from the nasal pharynx was described, and
reports of four prior cases were reviewed. The patient was a 41-year-old male who developed what appeared to be
typical hyperthyroidism and atrial fibrillation in 2009. Thyroid function tests showed elevated basal levels of free T3
(FT3, 24.08 pmol/L), free T4 (FT4, 75.73 pmol/L), and serum TSH (7.26 μIU/ml). Both TSH-oma and resistance to thyroid
hormone syndrome were considered. TRH stimulating test was negative, whereas octreotide inhibition test showed a
reduction in TSH by 30.8%. Furthermore, a large space-occupying lesion located at the nasopharynx was found by
computed tomography and magnetic resonance imaging (MRI). A normal pituitary was visualized. Ectopic TSH-oma
was preliminarily established. Using an endoscopic endonasal approach, the tumor was resected. Histological features
and immunophenotypes were consistent with those of TSH-secreting tumor. The levels of both free thyroxine and TSH
returned to normal ranges the day after surgery and remained within normal range for 48 months.
Conclusions: Although exceedingly rare, ectopic TSH-oma should be considered for patients with inappropriate
secretion of TSH with hyperthyroidism and pituitary tumor undetectable by computed tomography and MRI. To
our knowledge, this is the first case followed up more than 4 years. The characteristics and successful interventions
summarized in this report provide a guideline for clinicians.
Keywords: Ectopic TSH-secreting pituitary adenoma, Resistance to thyroid hormone (RTH), TRH stimulating test,
Octreotide inhibition test, HyperthyroidismBackground
TSH-secreting pituitary adenomas (TSH-omas) are an
unusual disorder, accounting for ~2% of all pituitary tu-
mors [1]. Ectopic TSH-oma is extremely rare. Since the
first description of the disease by Cooper and colleagues
in 1996, only four cases have been reported to date
[2-5]. Here a newly identified case is reported, and the
clinical and laboratory features of previous published
cases are reviewed.* Correspondence: whsmq1201@hotmail.com; james.ji@uthct.edu
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A 41-year-old male suffering from palpitations, dyspnea,
weight loss, and fatigue for one year was referred to
Weihai Municipal Hospital in June 2009. He also had
atrial fibrillation. Thyroid functional tests showed in-
creased FT3 (24.08, normal 2.8-7.1 pmol/L), FT4 (75.73,
normal 12-22 pmol/L), and TSH (7.26, normal 0.27-4.2
μIU/ml). He was diagnosed with hyperthyroidism and
given propylthiouracil (300 mg daily) together with ei-
ther propranolol or propafenone. The patient's electro-
cardiogram displayed sinus rhythm. The levels of FT3
and FT4 (FT3 11.54 pmol/L, FT4 27.09 pmol/L) but not
TSH (14.08 μIU/ml) were reduced after six months of
treatment. However, the concentration of free thyroid
hormones were still not normal. In sharp contrast, the
TSH level was further elevated after intensive treatment.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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rule out TSH-oma. The MRI image indicated a normal
pituitary gland (Figure 1A and B). Thus, resistance to
thyroid hormone syndrome was diagnosed, and triio-
dothyroacetic acid was prescribed. The plasma levels of
FT3, FT4, and TSH transiently decreased and then
rebounded.
Over the course of the disease, the patient lost 6 kg of
body weight. He had no symptoms of headache, nausea,
dizziness, subnormal vision, impaired visual field, and ob-
vious nasal obstruction. His physical examination was nor-
mal (T 36.7°C, P 80/min, R 17/min, BP120/80 mmHg, Ht
173 cm, Wt 65 Kg). He had a symmetrical figure, normal
hair distribution, sweaty skin, normal superficial lymph
nodes, and normal degree of convexity of eyeballs. Palpa-
tion revealed swelling of the thyroid gland, no nodules,
medium texture, and no haphalgesia. Vascular murmurFigure 1 MRI and CT images. A & B, MRI of the pituitary showing a norm
(white arrow). C & D, CT scan showing a 1.9 × 1.7 cm mass in the nasopharwas not heard on auscultation. The patient had uneven
cardiac sounds and arrhythmia with a heart rate of 100/
min. No abdominal abnormalities were found. The prox-
imal muscles did not show signs of atrophy. Mild tremor
was observed when he raised his hands. The patellar
tendon reflex was normal, and the pathological reflex
was not observed. Lab and imaging results showed nor-
mal liver and kidney. TG-Ab <30%, TM-Ab <15%, GH 0.7
(normal <5.0 ng/ml), FSH 16.8 (normal 1.5-12 mIU/ml),
LH 13.72 (normal 1.7-8.6 mIU/ml), PRL 14.9 (normal 4.1-
18.4 ng/ml), and T 13.20 (normal 2.8-8.0 ng/ml). The blood
electrolytes were within normal ranges: Ca 2.27 mmol/L,
P 1.23 mmol/L, and K 3.87 mmol/L. Tumor biomarkers
were analyzed, including carbohydrate antigen-199 12.26
(normal <37 U/ml), carcinoembryonic antigen 1.90
(normal <10 ng/ml), and neuron specific enolase (NSE)
22.31 (normal <16.3 ng/ml). Given a normal pituitaryal pituitary gland and an ectopic pituitary tumor in the nasopharynx
yngeal cavity (white arrows). E & F, CT scan 48 months post surgery.
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with gadolinium contrast, abnormal TSH level, and a large
space-occupying lesion within the nasal cavity and the
nasopharynx, with a maximum cross-section area of 1.9 ×
1.7 cm (Figure 1C & D), as detected by CT scan, an ec-
topic TSH-secreting pituitary tumor was suspected. Emis-
sion computed tomography (ECT) demonstrated strong
technetium-uptake by the thyroid. However, as shown in
Figure 2A, the stimulating test was negative for TSH level
was not up-regulated by TRH (Shanghai Lizhudongfeng
Biologic Technology Inc., China). The amount of TSH
was increased <2 μIU/ml. In comparison, the octreotide
inhibition test was positive; a decrease of up to 30.8% in
TSH level was observed (Figure 2B). Taken together, a
diagnosis of ectopic TSH-secreting tumor in the naso-
pharynx was tentatively established. The strategy to com-
bine resection and quick pathological examination was
proposed to release patient’s financial burden and surgical
stress. Nevertheless, his surgery was postponed due to
treatment of the atrial fibrillation.
The patient underwent endoscopic endonasal surgery,
through which the mass was removed in November
2009. Pathological examination confirmed invasive ec-
topic pituitary tumor extending to the bone parenchyma.
Microscopic examination showed that the unenveloped
tumor tissue lay beneath the nasal mucosa (pseudostrati-
fied ciliated columnar epithelium) (Figure 3A & B). The
tumor cells invading the mucosa and fibrous tissue led
to a tumor tissue type that was diffusive, solid lesion,
and sinusoidal. The irregular tumor cells were mostly
round or polygonal, while others were spindle shaped,
filled with rich cytoplasm bearing fine particles. Some
cells were found to have a round to ovoid nucleus with
transparent cytoplasm (Figure 3A & B). Immunohisto-
chemical assays detected expression of TSH (brown) and
GH (brown) (Figure 3C & D). No other pituitary hor-
mones, including ACTH, LH, FSH, and PRL, or thyro-
globulin and thyroid transcription factor1 were detectable.
In contrast, pan-cytokeratin, chromogranin, synaptophy-
sin, and neuron specific enolase were detected. ElectronFigure 2 TRH stimulating and octreotide inhibition tests. The unit for F
stimulating test. B, Octreotide inhibition test.microscopy examination found that the tumor was com-
posed of pleomorphic cells (Figure 3E and F). Round,
unenveloped electron-dense granules were dispersed
throughout the cytoplasm. Some granules formed clusters.
The diameter of granules was 0.1-0.2 μm.
Upon resection of the tumor, the levels of plasma
TSH, FT3, and FT4 returned to normal ranges, as ana-
lyzed 24 hours post surgery (Table 1). The patient gained
3 kg of body weight in two months. In addition, the
symptoms of sweating, palpitation, and fatigue disap-
peared. Atrial fibrillation was treated with metoprolol
and warfarin. We re-examined plasma TSH, FT3 and
FT4 levels 48 months post surgery and found them still
normal (Table 1). Meanwhile, CT scan did not indicate
recurrence of the tumor (Figure 1E & F).
Discussion
Ectopic TSH-omas are extremely rare. To date, only four
cases have been reported. In all five cases of ectopic
TSH-oma, including our patient, the tumor was located
in the nasopharynx. Their clinical and laboratory fea-
tures are summarized in Table 2.
This patient was diagnosed as ectopic TSH-oma in
November 2009. Similar to the other cases, the patient
went to see the doctor for hyperthyroidism with diffuse
goiter and atrial fibrillation; ophthalmopathy, pretibial
myxedema, and periodic paralysis were not presented.
Additionally, the previous four cases had a common spe-
cific symptom of airway obstruction resulting from space
occupying effects. Nevertheless, it was not evident in
this patient, leading to overlook of existence of tumor by
both the patient and physicians.
With regard to the phylogenetics of ectopic pituitary
adenoma, it is broadly accepted that the tumor is de-
rived from the embryonic residues of pituitary cells
along the path of migration of Rathke's pouch. The an-
terior pituitary primordium appears at the fourth week
of embryogenesis. The pituitary then divides into sellar
and pharyngeal parts in the eighth week. The cranio-
pharyngeal canal allows for migration of the pituitaryT3 and FT4 is pmol/L, for PRL is ng/ml, and for sTSH is μIU/ml. A, TRH
Figure 3 Histological examination of resected tumor tissue. A & B, Histological examination of resected tumor tissue (×200). A, Irregular cells
showing tumor tissue invasive growth involving the submucosa. B, Cytoplasm is filled with fine granules in tumor cells. C & D, Immunohistochemical
detection of TSH and GH (×200). C, Most tumor cells express TSH (brown). D, Expression of GH in tumorous cells. E & F, Electron microscopy examination
of tumor tissue. Numerous round electron dense granules about 100-200 nm in size are seen in the cytosol. Bar = 0.5 μm.
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Nasopharyngeal and sphenoid sinus or sphenoid bone
ectopic pituitary tissue can be fully functional, since
pharyngeal pituitary tissue begins to produce hormones
around the 17-18th week of gestation (about 8 weeksTable 1 Plasma thyroid hormone and TSH levels




2009-07-12 4.23 191.23 14.30
2009-11-12 4.85
2013-11-17 5.28
The normal range for each assay is included in brackets.
The unit for T3 and T4 is nmol/L, for FT3 and FT4 is pmol/L, and for TSH is μIU/ml.later than sellar pituitary function begins) [6]. Landolt
and co-workers found that 90 - 100% of adults had ec-
topic pituitary tissue in the sphenoid sinus/bone [7]. The
pharyngeal hypophysis released all six normal pituitary
hormones (ACTH, TSH, PRL, LH, FSH, and GH) [8]. ItFT4 TSH Remarks
0) (12.0–22.0) (0.27–4.20)
75.73 7.26 PTU 300 mg/d
27.09 14.08 PTU 300 mg/d
29.86 5.72 PTU 300 mg/d
13.54 1.86 24 h post surgery
19.26 0.65 48 m post surgery
Table 2 Comparison of five ectopic TSH-omas
Case number First Second Third Fourth Fifth
Reference 2 3 4 5 This report
Gender F M F F M
Age of onset (y) 45 34 - 34 40
Age of diagnosis 66 52 50 49 41
Location of tumor nasopharynx










IHC TSH(+) TSH(+) TSH(+) TSH(+) TSH(+)
GH(+) GH(-) GH(+) GH(+) GH(+)
PRL(+) PRL(-) PRL(-) PRL(+) PRL(-)
FSH(+) FSH(-) FSH(+) FSH(-) FSH(-)
ACTH(+) ACTH(-) ACTH(-) ACTH(-) ACTH(-)
LH(+) LH(-) LH(+) LH(-) LH(-)
Ultrastructure N/A N/A N/A consisted of monomorphous cells
with secretory granules of small
thyrotroph-like cells
consisted of polymorphous
cells with secretory granules
Octreotide inhibition test N/A N/A N/A yes yes
TRH stimulating test N/A N/A N/A N/A yes
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cells produce tumor lesion, and synthesize pituitary
hormones.
Of note, the first case received radioactive iodine treat-
ment without prior measurement of the TSH level. Al-
though hyperthyroidism was abrogated, the consequence
was hypothyroidism with an increased level of TSH. This
obscured the nature of the disease and complicated the
diagnostic process. This was the only case that received
radiation therapy for the thyroid prior to final diagnosis.
Therefore, it was difficult to determine whether the tumor
was a primary ectopic TSH-secreting tumor or resulted
from radioiodine thyroid ablation-induced hypothyroidism.
Remission of the latter could be achieved by administration
of thyroid hormones. Indeed, invasive transformation of
the tumor and high occurrence of invasive macroadeno-
mas were described in patients with previous thyroid abla-
tion by surgery or radioiodine. It resembled the occurrence
of Nelson’s syndrome after adrenalectomy for Cushing’s
disease.
Ectopic TSH-oma and pituitary TSH-secreting tumor in
the sellar area cannot be differentiated by their biological
characteristics. Both present high levels of serum FT3 and
FT4, in addition to either normal or high level of TSH.
The difference between these two tumor types is that the
ectopic TSH-oma has a normal pituitary gland and sellar
turcica. Nowadays, with high-resolution CT and MRI,
large pituitary adenomas are easy to find; moreover, it is
not difficult to detect micro-adenomas either [9,10].
It is not easy to distinguish TSH-oma from resistance
to thyroid hormones (RTH) (Figure 4). RTH is rare,more than 90% of RTH are hereditary, displaying auto-
somal dominant inheritance, which are linked to muta-
tions of thyroid hormone receptor β gene. RTH also
exhibits high FT3 and FT4 levels and inappropriate TSH
secretion. In addition, there were no significant differ-
ences in the basal values of TSH and free thyroid hor-
mones between TSH-secreting tumor and RTH [11,12].
Hence, other diagnostic measures are required. Glyco-
protein hormone subunits (α-GSU) and molar ratio of
α-GSU/TSH are valuable indicators to distinguish TSH-
secreting tumor from RTH. More than 80% of TSH-
secreting tumors had hypersecretion of circulating free α-
GSU and an elevated α-GSU/TSH molar ratio [9,12,13]. It
was more common in macroadenomas than in micro-
adenomas [9]. The pituitary adenoma causing hyperthy-
roidism is composed of two types of cells, one secreting
α-GSU alone, and the other producing both α-GSU and
thyrotropin but not in equal amounts [14]. Generally,
α-GSU is secreted more than TSH. However, in this
case, α-GSU was not detected. Furthermore, TSH-oma
displayed an elevation in sex-hormone-binding globu-
lin, while it was normal in RTH [12]. The final diagno-
sis was made by TRH stimulating and octreotide
inhibition tests. While 96% of TSH-secreting tumor
presented a blunted TSH response to the TRH test and
97% of RTH were excited by TRH [12]. This patient
presented a blunted TSH response to the TRH test
(Figure 2A). Most pituitary TSH-secreting tumor cells
possess somatostatin receptors, which are sensitive to
somatostatin and its analogues. FT3 and FT4 levels de-
creased markedly following delivery of somatostatin
Figure 4 Differential diagnosis of TSH-omas. α-GSU, α-glycoprotein hormone subunits; SHBG, sex-hormone binding globulin; TRH, thyroptroin
releasing hormone; TRβ, thyroid hormone receptor β.
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Similarly, the inhibitory effect of octreotide was seen in
ectopic TSH-oma too [5]. This patient presented a sig-
nificant inhibitory response to octreotide (Figure 2B),
and the inhibitory effect of octreotide on ectopic TSH-
oma cells was also confirmed in vitro [5]. In addition,
TSH-secreting tumor cells possessed dopamine recep-
tors. The presence of dopamine receptors in TSH-omas
was the rationale for therapeutic trials with dopaminergic
agonists. Several studies, however, have shown a large het-
erogeneity of TSH responses to dopaminergic agents
[13,15]. In fact, administration of dopamine agonists failed
to persistently block TSH secretion in almost all patients
and caused tumor shrinkage only in those with combined
hypersecretion of TSH and PRL [16].
TSH-omas are generally benign tumors. However, trans-
formation of TSH-oma into carcinoma with multiple me-
tastases and loss of pituitary α-GSU has been reported
[17]. TSH-secreting carcinoma could also develop from
previously non-functioning pituitary adenoma [18]. All
five cases of ectopic TSH-omas had characteristics of be-
nign tumors. Although tumors of some cases invaded into
adjacent tissues, none showed distant metastasis [3].
Morphological characteristics of tumor cells were incon-
sistent including unitary shape, irregular morphology, and
multiple types of cells. Cells contained abundant granular
cytoplasm and round or oval nuclei. Relatively largeamounts of blood sinuses existed in the tumor. The aden-
oma consisted of monomorphous cells as visualized by
electron microscopy. Numerous secretory granules were
scattered across the cytoplasm or along the cell membrane
[5]. They were similar in size and shape of electron dense
with a diameter of 60-120 [5]. In comparison, the tumor
cells of this case were pleomorphic, and the size of their
electron dense granules was larger with a diameter of 100-
200 nm, and were scattered or clustered in the cytoplasm.
Immunohistochemical examination is essential for study-
ing the nature of the tumor cells and hormone secretion.
Almost all neuroendocrine tumors have enhanced ex-
pression of chromogranin A, synaptophysin, and neuron-
specific enolase [6,19]. Therefore, these proteins have been
used as biomarkers of neuroendocrine tumor. Except for
the case reported by Collie, strong expression of various
neuroendocrine biomarkers, including chromogranin A,
synaptophysin, and neuron-specific enolase was confirmed.
As for cell proliferation, the amount of Ki-67-positive cells
was less than 2%, suggesting that cell proliferation of the
ectopic TSH-oma was low, in agreement with what was
known of TSH-oma in situ. The types of hormones se-
creted by ectopic TSH-oma were not identical (Table 2).
Except for the second case, GH expression in the tumor
tissues was detected. In addition, augmentation of the ex-
pression of TSH and GH was also described in vitro [5].
However, the serum level of GH in the fourth patient was
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manifestation in vivo [20,21]. The mechanism remains un-
clear. It may be due to lesser secretion of secondary hor-
mone or limited release into blood.
The therapeutic approach in all five cases was adeno-
mectomy. The primary objectives of the surgical treat-
ment were to remove the ectopic TSH-oma, to eliminate
the excessive secretion of TSH, and to restore euthyroid-
ism. The prerequisite was to reduce the level of thyroid
hormone to ease thyrotoxicosis prior to adenomectomy.
The most common strategy is to take either anti-thyroid
drugs (methimazole 20-30 mg/d or propylthiouracil 200-
300 mg/d) or somatostatin analogs (octreotide, 100 μg,
s.c., bid or tid. Sandostatin®, Novartis Pharma Schweiz
AG, Switzerland) as well as propranolol (80-120 mg/d
orally). Obviously, somatostatin analogs should be pre-
ferred theoretically, and this has been borne out in prac-
tice. For example, the TSH level of the fourth case
returned to normal one day post octreotide treatment
(100 μg, ih, q8h). Meanwhile, the levels of FT3 and FT4
declined to normal in 7 days. In contrast, it was difficult
to control TSH and thyroid function with anti-thyroid
drugs. In this case, PTU (300 mg/d) could not reduce
free thyroxine to normal levels (Table 1). TSH and free
thyroxine levels were normal within a few days [22],
even within 24 hr after surgery in our case study. Appar-
ently, it is feasible to treat TSH-omas by in situ radio-
therapy. However, this intervention was not applied to
all five cases of ectopic TSH-omas [2-5].
Given that somatostatin (somatotropin release-inhibiting
hormone, SRIH) receptor was expressed in TSH-omas
[23,24], somatostatin analogues have been used to treat
TSH-oma in situ. Somatostatin analogues are potent in
reducing TSH secretion. Long-acting somatostatin ana-
logues, including octreotide LAR, lanreotide SR, and
lanreotide autogel were preferred [9,10,25,26]. These
medicines decreased TSH and α-GSU secretion, and re-
stored euthyroidism. Circulating thyroid hormone levels
were normalized in more than 95% of patients, and pituit-
ary tumor mass shrinkage occurred in approximately 40%
of patients [12]. Furthermore, the efficiency of the somato-
statin analogue was observed in an ectopic TSH-oma
patient [5].
Conclusions
In toto, ectopic TSH-oma is extremely rare. To date, only
four cases have been reported. The phylogenetic mechan-
ism of ectopic TSH-oma should be similar to other ec-
topic pituitary tumors, which are probably derived from
the embryonic residues of pituitary cells along the path of
migration of Rathke's pouch. All five cases were found to
have a mass in the nasopharyngeal region. Their clinical
manifestations were almost the same as those of ordinary
hyperthyroidism (high metabolic syndrome). Nevertheless,they all had high levels of TSH as well as increased serum
free thyroxine. Alpha-GSU and α-GSU/TSH ratio are
valuable for distinguishing TSH-oma from other diseases.
Moreover, TRH stimulating and octreotide inhibition
tests could differentiate ectopic TSH-oma from RTH.
The primary therapy for ectopic TSH-oma is the resec-
tion of adenoma. Nonsurgical intervention through
long-acting somatostatin analogues can suppress TSH
secretion. Whether in situ radiation therapy could be
an effective intervention remains unknown.
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